MCID: INF067
MIFTS: 23

Inflammatory Bowel Disease 10

Categories: Genetic diseases, Gastrointestinal diseases, Rare diseases, Bone diseases, Blood diseases, Immune diseases

Aliases & Classifications for Inflammatory Bowel Disease 10

MalaCards integrated aliases for Inflammatory Bowel Disease 10:

Name: Inflammatory Bowel Disease 10 54 12 71
Inflammatory Bowel Disease 10 12 71 29 13 69
Ibd10 12 71

Classifications:



External Ids:

OMIM 54 611081
Disease Ontology 12 DOID:0110885
MedGen 40 C1970207
MeSH 42 D015212

Summaries for Inflammatory Bowel Disease 10

UniProtKB/Swiss-Prot : 71 Inflammatory bowel disease 10: A chronic, relapsing inflammation of the gastrointestinal tract with a complex etiology. It is subdivided into Crohn disease and ulcerative colitis phenotypes. Crohn disease may affect any part of the gastrointestinal tract from the mouth to the anus, but most frequently it involves the terminal ileum and colon. Bowel inflammation is transmural and discontinuous; it may contain granulomas or be associated with intestinal or perianal fistulas. In contrast, in ulcerative colitis, the inflammation is continuous and limited to rectal and colonic mucosal layers; fistulas and granulomas are not observed. Both diseases include extraintestinal inflammation of the skin, eyes, or joints.

MalaCards based summary : Inflammatory Bowel Disease 10, is also known as inflammatory bowel disease 10. An important gene associated with Inflammatory Bowel Disease 10 is ATG16L1 (Autophagy Related 16 Like 1). The drugs Ciprofloxacin and Adalimumab have been mentioned in the context of this disorder. Affiliated tissues include colon, skin and bone.

Disease Ontology : 12 An inflammatory bowel disease that has material basis in variation in the ATG16L1 gene on chromosome 2q37.

Description from OMIM: 611081

Symptoms & Phenotypes for Inflammatory Bowel Disease 10

Clinical features from OMIM:

611081

Drugs & Therapeutics for Inflammatory Bowel Disease 10

Drugs for Inflammatory Bowel Disease 10 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 232)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 85721-33-1 2764
2
Adalimumab Approved Phase 4,Phase 3,Phase 1,Phase 2 331731-18-1 16219006
3
Infliximab Approved Phase 4,Phase 3,Phase 2,Phase 1 170277-31-3
4
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 50-24-8 5755
5
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
6
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 83-43-2 6741
7
Midazolam Approved, Illicit Phase 4,Phase 1 59467-70-8 4192
8
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
9
Azathioprine Approved Phase 4,Phase 3 446-86-6 2265
10
Azithromycin Approved Phase 4 83905-01-5 55185 53477736 447043
11
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
12
Metronidazole Approved Phase 4,Phase 3,Phase 1,Early Phase 1 443-48-1 4173
13
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
15 Vedolizumab Approved Phase 4,Phase 3,Phase 2 943609-66-3
16
Prednisone Approved, Vet_approved Phase 4,Phase 3 53-03-2 5865
17
Nicotine Approved Phase 4 54-11-5 942 89594
18
Zinc Approved Phase 4 7440-66-6 32051 23994
19
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754 657311
20
Copper Approved Phase 4 7440-50-8 27099
21
Vancomycin Approved Phase 4 1404-90-6 441141 14969
22
Thioguanine Approved Phase 4 154-42-7 2723601
23
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2 1406-16-2
24
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 1,Phase 2 50-14-6 5280793
25
leucovorin Approved, Nutraceutical Phase 4,Phase 3 58-05-9 143 6006
26
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
27 Tocopherol Approved, Nutraceutical Phase 4,Phase 2
28
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-30-3 6037
29
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 59-02-9 14985
30
Butyric Acid Experimental Phase 4 107-92-6 264
31 Prednisolone acetate Phase 4,Phase 3,Phase 1,Phase 2
32 glucocorticoids Phase 4,Phase 3,Phase 1,Phase 2
33 6-Mercaptopurine Phase 4,Phase 3,Phase 2
34 Methylprednisolone acetate Phase 4,Phase 3,Phase 1,Phase 2
35 Methylprednisolone Hemisuccinate Phase 4,Phase 3,Phase 1,Phase 2
36 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Neuroprotective Agents Phase 4,Phase 3,Phase 1,Phase 2
38 Cytochrome P-450 CYP1A2 Inhibitors Phase 4,Phase 3,Phase 2
39 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2
40 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2
41 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
42 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
44 Hormones Phase 4,Phase 3,Phase 1,Phase 2
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
46 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
47 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Early Phase 1
48 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1
50 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 304)

id Name Status NCT ID Phase Drugs
1 "Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial" Unknown status NCT02452151 Phase 4 Infliximab-Biosimilar;Infliximab-Innovator
2 Participation and Detection Rate Diagnostic of a Colorectal Cancer Screening Program: CT Colonography vs. Flexible Sigmoidoscopy Unknown status NCT01739608 Phase 4
3 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Unknown status NCT01632462 Phase 4 VSL#3
4 Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease Unknown status NCT00609752 Phase 4 prednisolone
5 Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy Unknown status NCT00851565 Phase 4
6 Vitamin D in Pediatric Crohn's Disease Completed NCT01187459 Phase 4
7 Satisfaction With Nurse Administered Propofol Sedation vs. Midazolam With Fentanyl Sedation for Endoscopy Completed NCT01934088 Phase 4 Propofol;Midazolam;Fentanyl
8 Treatment of Ulcerative Colitis With Ciprofloxacin and E. Coli Nissle Completed NCT01772615 Phase 4 Ciprofloxacin
9 Immune Modulation by Parenteral Fish Oil in Patients With Crohn's Disease Completed NCT02349594 Phase 4 Omegaven 10%;Intralipid 20%
10 Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease Completed NCT01596894 Phase 4 Azithromycin + Metronidazole;Metronidazole
11 A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients Completed NCT00207688 Phase 4 Infliximab 5 mg/kg;Infliximab 10 mg/kg;Placebo
12 Evaluation of the Applicability of the CDEIS to Data Obtained by the Colonic Capsule Endoscopy in Crohn Disease Completed NCT01183845 Phase 4
13 Study Investigating Tailored Treatment With Infliximab for Active Crohn's Disease Completed NCT01442025 Phase 4 Infliximab;Infliximab;Infliximab
14 Once Versus Twice Daily Mesalamine to Induce Remission in Pediatric Ulcerative Colitis Completed NCT01201122 Phase 4 Mesalamine
15 An Efficacy and Safety Study of Infliximab in Pediatric Participants With Inflammatory Bowel Disease Recruiting NCT02566889 Phase 4 Infliximab
16 Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With IBD Recruiting NCT02774057 Phase 4 Captafer®;Iron Sulfate
17 Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab Recruiting NCT02453776 Phase 4 PRECISION dosing Infliximab
18 Thiopurine Induced Pancreatitis in IBD Patients Recruiting NCT02281799 Phase 4 Azathioprine
19 Manipulating the Microbiome in IBD by Antibiotics and FMT Recruiting NCT02033408 Phase 4 AB (antibiotics);CS (corticosteroids) Only
20 Value of Pharmacokinetic Assays in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease Recruiting NCT02768532 Phase 4 Vedolizumab
21 A Study to Evaluate Efficacy, of Early Versus Late Use of Vedolizumab in Crohn's Disease: the LOVE-CD Study Recruiting NCT02646683 Phase 4 vedolizumab
22 Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis Recruiting NCT02770040 Phase 4 Infliximab
23 Corticosteroids With Vedolizumab in Crohn's Disease Recruiting NCT02324699 Phase 4 Prednisone;Placebo;Vedolizumab
24 Golimumab Dried Blood Spot Analysis Recruiting NCT02910375 Phase 4
25 Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis Recruiting NCT02345733 Phase 4 Antibiotic cocktail
26 Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease Recruiting NCT02630966 Phase 4 Vedolizumab;Placebo
27 Mesalazine With Hydrocortisone Sodium Succinate Enema for 4-Week Treatment in Patients With Ulcerative Colitis Recruiting NCT03110198 Phase 4 Mesalazine;hydrocortisone sodium succinate;Mesalazine with hydrocortisone sodium succinate
28 Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial Active, not recruiting NCT02256462 Phase 4 Adalimumab
29 Anemia in Inflammatory Bowel Disease Not yet recruiting NCT02760940 Phase 4 oral liposomal iron
30 Intermittent Treatment After Reaching the taRget With Golimumab for ulcErative coliTis - (TARGET) Not yet recruiting NCT02425865 Phase 4 GOLIMUMAB
31 Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels Not yet recruiting NCT03124121 Phase 4 Golimumab
32 Treatment With Infliximab in a Medical Setting (Study P05587) Terminated NCT00752622 Phase 4
33 Effectiveness and Safety of Spondylitis Related to Inflammatory Bowel Disease Withdrawn NCT00972218 Phase 4
34 Adalimumab for the Management of Post-operative Crohn's Disease (CD) Unknown status NCT01629628 Phase 3 Adalimumab;6 Mercaptopurine
35 The Effect of a Probiotic Preparation (VSL#3) Plus Infliximab in Children With Crohn's Disease Unknown status NCT01548014 Phase 3
36 Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2) Completed NCT01352221 Phase 3 ST10-021;Placebo Comparator
37 Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Ulcerative Colitis (AEGIS-1) Completed NCT01340872 Phase 3 ST10-021;Placebo Comparator
38 An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Crohn's Disease Completed NCT00269854 Phase 2, Phase 3 Infliximab 5 mg/kg;Infliximab 10 mg/kg;Infliximab 20 mg/kg;Placebo
39 FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR Completed NCT00810030 Phase 3 Ferric carboxymaltose;Iron Sucrose
40 Evaluation of Topical 10% Metronidazole Ointment for the Treatment of Active Perianal Crohn's Disease Completed NCT00509639 Phase 3 10% Metronidazole Ointment
41 A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative Colitis Completed NCT00336492 Phase 3
42 Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease Completed NCT00409682 Phase 3
43 A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease Completed NCT01277666 Phase 3 GSK1605786A;GSK1605786A;Placebo
44 An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Fistulizing Crohn's Disease Completed NCT00269841 Phase 3 Infliximab 10 mg/kg;Infliximab 5 mg/kg;Placebo
45 Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease Completed NCT01580670 Phase 3 TA-650
46 A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis Completed NCT01458574 Phase 3 Placebo;CP690,550;CP-690,550
47 Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870). Completed NCT00152425 Phase 3 Certolizumab Pegol (CDP870)
48 A Study of Abatacept in Patients With Active Ulcerative Colitis Completed NCT00410410 Phase 3 abatacept (ABA);placebo;abatacept
49 Mucosal Healing Study in Crohn's Disease (CD) Completed NCT00297648 Phase 3
50 A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis Completed NCT01465763 Phase 3 tofacitinib;Placebo

Search NIH Clinical Center for Inflammatory Bowel Disease 10

Genetic Tests for Inflammatory Bowel Disease 10

Genetic tests related to Inflammatory Bowel Disease 10:

id Genetic test Affiliating Genes
1 Inflammatory Bowel Disease 10 29

Anatomical Context for Inflammatory Bowel Disease 10

MalaCards organs/tissues related to Inflammatory Bowel Disease 10:

39
Colon, Skin, Bone, Eye, Testes, Liver, T Cells

Publications for Inflammatory Bowel Disease 10

Variations for Inflammatory Bowel Disease 10

UniProtKB/Swiss-Prot genetic disease variations for Inflammatory Bowel Disease 10:

71
id Symbol AA change Variation ID SNP ID
1 ATG16L1 p.Thr300Ala VAR_021834 rs2241880

Expression for Inflammatory Bowel Disease 10

Search GEO for disease gene expression data for Inflammatory Bowel Disease 10.

Pathways for Inflammatory Bowel Disease 10

GO Terms for Inflammatory Bowel Disease 10

Sources for Inflammatory Bowel Disease 10

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....